Clinical trials: Lymphoma, Non-Hodgkin
Lymphomas
CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
Currently, a majority of lymphomas cannot be cured by standard chemo-radiotherapy. Cluster of differentiation antigen 30 (CD30) is expressed in many lymphoma subtypes, such as Hodgkin lymphoma (HL) and anaplastic large cell…
- Trial name
- NCT02274584
- Testing
- Anti-CD30 CAR T cells
- Where
- 2 sites in United States, China
- Volunteers
- 20 people
- Sponsor
- Peking University
Lymphoma, Extranodal NK-T-Cell
Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL
To evaluate the efficacy and safety of first-line gemcitabine, oxaliplatin, and asparaginase (GELOX) with concurrent involved-field radiation therapy for patients in newly diagnosed stage IE/IIE ENKTL.
- Trial name
- NCT02080234
- Testing
- GELOX, IFRT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed).
- Trial name
- NCT04546399
- Testing
- 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection
- Where
- 227 sites in United States, Australia and 2 more
- Volunteers
- 461 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral T-Cell Lymphoma
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-cell lymphoma.
- Trial name
- NCT01841021
- Testing
- Brentuximab vedotin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.
- Trial name
- NCT00435916
- Testing
- SGN-40
- Where
- 14 sites in United States
- Volunteers
- 46 people
- Sponsor
- Seagen Inc.
Orthopaedic Fractures
Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)
The purpose of this study is to definitively resolve questions regarding the use of multimodal pharmacologic pain management for orthopedic trauma patients in the context of a multicenter, randomized clinical trial.
- Trial name
- PAIN (NCT01789216)
- Testing
- NSAID, Gabapentinoids
- Where
- 17 sites in United States
- Volunteers
- 450 people
- Sponsor
- Major Extremity Trauma Research Consortium
Untreated CD20-positive Large B-cell Lymphoma
Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma
Evaluation of the efficacy of a single injection of Pegfilgrastim (6mg) administered at day 3 of each cycle of R-ACVBP regimen during 4 cycles in patients with CD20+ diffuse large B-cell lymphoma presenting at least 2 adverse…
- Trial name
- NCT00169143
- Testing
- Rituximab + ACVBP regimen plus Pegfilgrastim, Autologous stem cell transplant
- Where
- 6 sites in France
- Volunteers
- 60 people
- Sponsor
- Lymphoma Study Association
Large B-Cell Diffuse Lymphoma
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.
- Trial name
- NCT03450343
- Testing
- Oral azacitidine, R-ICE
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medical University of South Carolina
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase I trial to study the effectiveness of geldanamycin analogue in treating patients who have advanced solid tumors or non-Hodgkin's lymphoma.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma
- Trial name
- NCT00019708
- Testing
- tanespimycin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin Lymphoma
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma…
- Trial name
- SUNMO (NCT05171647)
- Testing
- Mosunetuzumab, Polatuzumab vedotin, Tocilizumab
- Where
- 50 sites in United States, Argentina and 11 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
This study evaluates the efficacy and safety of penpulimab plus lenalidomide, rituximab, gemcitabine and oxaliplatin (R2-GemOx) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT05186558
- Testing
- penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
- Where
- 4 sites in China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth.
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- NCT04257578
- Testing
- Acalabrutinib, Axicabtagene Ciloleucel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Washington
OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
Clinical Study of OR for Second-line Treatment of Refractory MZL
The goal of this clinical trial is to test the overall response rate of Orelabrutinib combined with rituximab (OR regimen) for second-line treatment of relapsed/refractory marginal zone lymphoma.
- Trial name
- NCT06134284
- Testing
- Orelabrutinib combined with rituximab
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Lixia Sheng
Mantle Cell Lymphoma
Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)
This is a single arm, multi-center, open label Phase Ib/II trial in adult patients with newly diagnosed Mantle Cell Lymphoma (MCL)(Stage II-IV).
- Trial name
- CHOP U2 (NCT04692155)
- Testing
- Ublituximab, Umbralisib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Anaplastic Large-Cell Lymphoma
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
To investigate safety and antitumor activity of SGN-30 in patients with Hodgkin's Disease and anaplastic large cell lymphoma (ALCL).
- Trial name
- NCT00079755
- Testing
- SGN-30 (anti-CD30 mAb)
- Where
- 18 sites in United States
- Volunteers
- 80 people
- Sponsor
- Seagen Inc.
Lymphoma
Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00234026
- Testing
- gemcitabine hydrochloride
- Where
- 16 sites in Switzerland
- Sponsor
- Swiss Cancer Institute
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Mantle Cell Lymphoma
Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL
This is a prospective, multicenter, single arm, phase II trial designed to evaluate activity and the safety of the combination of Carfilzomib (K), Lenalidomide (R) and Dexamethasone (D) in patients with mantle cell lymphoma (MCL)…
- Trial name
- FIL_KLIMT (NCT03891355)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 11 sites in Italy
- Volunteers
- 16 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Burkitt's Lymphoma, Lymphoblastic Lymphoma
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
The goal of this clinical research study is to find the highest tolerable dose of the drugs clofarabine and cyclophosphamide that can be given together in the treatment of relapsed or refractory ALL.
- Conditions
- Burkitt's Lymphoma, Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia
- Trial name
- NCT00412243
- Testing
- Clofarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
RATIONALE: ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn…
- Conditions
- Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00387608
- Testing
- veliparib, pharmacological study, biopsy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.